The primary endpoints were time to diagnosis of CDMS

About BENEFIT – conducted BENEFIT is a multi-center study in 98 centers in 20 countries and patients with a first clinical episode of MS and typical MRI findings. The primary endpoints were time to diagnosis of CDMS , rigorous, to confirmed EDSS and patient reported quality of life outcomes . A total of 468 patients were randomized to get either 250 micrograms of interferon beta-1b receive every other day or placebo as a subcutaneous injection in a double-blind fashion . The placebo – controlled treatment period lasted up to 24 months or until such time when the patient a second attack and were diagnosed with clinically definite MS. All study participants were then invited to attend a follow-up study with prospectively Betafero involve the impact of early compared with delayed treatment Betafero on the long-term course of the disease for a total observation time for five years. The results in the medical journal Lancet reported are from a planned analysis at three years.

About Betafero / BetaseroBetafero, which is marketed in the U.S. And Canada under the trade name Betasero, was the first disease-modifying drug introduced for MS and is an established treatment around the world. In the U.S., Europe and Japan, has been approved for all Betafero relapsing forms of MS. It is able to of MS episodes of MS episodes by one-third, the frequency of moderate to severe episodes by by as much as 50 %. Treatment sixteen year follow-up for people with Betafero has shown that it is safe and well tolerated.

The UK National Stem Cell Network acts as a network existing regional stem cells networks in the UK, at bring ensure coordination and coherence to a series of national and regional activities the field of stem cell research. At first The UKNSCN Office receives financial support from four of the Germany Research Councils:.

Related Posts

Other Posts From Category "herbal medicine":